Accéder au contenu
Merck
  • Generation of two Duchenne muscular dystrophy patient-specific induced pluripotent stem cell lines DMD02 and DMD03 (MUNIi001-A and MUNIi003-A).

Generation of two Duchenne muscular dystrophy patient-specific induced pluripotent stem cell lines DMD02 and DMD03 (MUNIi001-A and MUNIi003-A).

Stem cell research (2019-09-19)
Sarka Jelinkova, Lenka Markova, Martin Pesl, Iveta Valáškova, Eva Makaturová, Lenka Jurikova, Petr Vondracek, Alain Lacampagne, Petr Dvorak, Albano C Meli, Vladimir Rotrekl
RÉSUMÉ

Duchenne muscular dystrophy (DMD) affects 1:3500-5000 newborn boys and manifests with progressive skeletal muscle wasting, respiratory failure and eventual heart failure. Symptoms show different onset from patients' childhood to the second decade of age. We reprogrammed fibroblasts from two independent DMD patients with a complete loss of dystrophin expression, carrying deletions of exons 45-50 and 48-50. The resulting hiPSCs show expression of pluripotency markers (NANOG, OCT4, SSEA4), differentiation capacity into all three germ layers, normal karyotype, genetic identity to the originating parental fibroblasts and the patient-specific dystrophin mutation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Alkaline Phosphatase Blue Microwell Substrate, sufficient for 400 mL working substrate